Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.60 |
| ▸ | GAA | P10253 | 7/20 | 0.60 |
| ▸ | RAB9A | P51151 | 7/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.60 |
| ▸ | GLA | P06280 | 5/20 | 0.60 |
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 7/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31197646 | 1.00 | PDE5A (0.72) | PDE5AKDM4EALDH1A1GAARAB9A | |
| SCHEMBL10754329 | 0.85 | KDM4E (0.59) | PDE5AKDM4EALDH1A1GAARAB9A | |
| SCHEMBL10802934 | 0.84 | ALDH1A1 (0.62) | PDE5AKDM4EALDH1A1GAARAB9A | |
| SCHEMBL7283626 | 0.84 | KDM4E (0.66) | PDE5AKDM4EALDH1A1GAARAB9A | |
| SCHEMBL7290108 | 0.83 | RAB9A (0.58) | PDE5AKDM4EALDH1A1GAARAB9A | |
| Bromide SCHEMBL10798312 | 0.83 | KDM4E (0.64) | PDE5AKDM4EALDH1A1GAARAB9A | |
| SCHEMBL10797862 | 0.81 | KDM4E (0.55) | PDE5AKDM4EALDH1A1GAARAB9A | |
| SCHEMBL10793366 | 0.80 | KDM4E (0.54) | PDE5AKDM4EALDH1A1GAARAB9A | |
| SCHEMBL10753739 | 0.80 | KDM4E (0.54) | PDE5AKDM4EALDH1A1GAARAB9A | |
| SCHEMBL7281389 | 0.79 | KDM4E (0.59) | PDE5AKDM4EALDH1A1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064945-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2025-02-27 | — | — | US | disclosed |
| EP-4436965-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2023096987-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023096987-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| EP-1836206-B1 | AZOLOPYRIMIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL MYERS SQUIBB CO (US) | 2011-03-09 | — | — | EP | disclosed |
| US-7635699-B2 | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635699-B2 | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635699-B2 | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-22 | — | — | US | disclosed |
| EP-1836206-A1 | AZOLOPYRIMIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | Bristol-Myers Squibb Company (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20060178377-A1 | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-08-10 | — | — | US | disclosed |
| WO-2006071752-A1 | AZOLOPYRIMIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006071752-A1 | AZOLOPYRIMIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178377-A1 | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | DPP4, DPP9, DPP3 | PDE5A 899/4885KDM4E 943/4885ALDH1A1 419/4885 |
| US-20250064945-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRAP, VHL | PDE5A 4467/4885KDM4E 2143/4885ALDH1A1 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.